Sanofi Consumer Healthcare
Sanofi Consumer Healthcare
HealthcareKey Fundamentals
MicrocapPharmaceuticalsHealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 77.6%
- Company has been maintaining a healthy dividend payout of 49.3%
Weaknesses
1- Stock is trading at 26.6 times its book value
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 69d agoSanofi Consumer Healthcare India Ltd trades at a market cap of ₹10,640 Cr with a PE of 41.3x and price-to-book of 27.76x. The company delivered TTM sales growth of 38% and profit growth of 35%, while maintaining a 3-year ROE of approximately 78% with virtually no debt on its balance sheet.
- Company is almost debt-free, providing significant financial flexibility and resilience against interest rate cycles
- Exceptional 3-year ROE of 78% indicates highly efficient capital allocation and strong competitive moat in its product portfolio
- TTM compounded sales growth of 38% demonstrates robust top-line momentum in the consumer healthcare segment
- TTM compounded profit growth of 35% shows strong earnings acceleration alongside revenue growth
- Last year ROE of 72% confirms consistent high returns are being sustained, not a one-off occurrence
- Healthy dividend payout ratio of 49.3% with a current yield of 1.62% provides regular income to shareholders
- Backed by global Sanofi parentage, offering access to R&D pipelines, brand equity, and operational best practices in consumer healthcare
- Company is expected to deliver a good upcoming quarter based on operational trends, potentially extending the growth streak
- Stock trades at 27.76x book value, an extremely elevated valuation that leaves minimal margin of safety for investors
- PE ratio of 41.3x is significantly above the broader market average, pricing in substantial future growth that must be delivered consistently
- Stock price has declined 14% over the past 1 year, indicating negative price momentum despite strong fundamentals
- Limited long-term historical data available — 5-year and 10-year CAGR figures for sales, profit, and stock returns are not reported, making long-term trend assessment difficult
- 52-week high and low data are unavailable (showing 0), limiting ability to assess current price relative to recent trading range
- Market cap of ₹10,640 Cr in a niche consumer healthcare segment may constrain institutional interest and liquidity compared to larger pharma peers
- Dividend yield of 1.62% is modest relative to the premium valuation being paid, offering limited downside protection
- High ROE of 72-78% partly reflects a very low equity base (as evidenced by 27.76x P/B), which can amplify apparent returns without proportional economic value creation
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 69d ago- Rs 75 final dividend declared Jun 26
Sanofi Consumer Healthcare India declared a final dividend of Rs 75 per share for FY25 at its 3rd AGM held on June 26, 2026, signaling strong cash generation and shareholder return commitment.
TL;DR: Sanofi Consumer Healthcare India is returning significant cash to shareholders with a Rs 75/share dividend for FY25, reflecting healthy profitability. No headwinds or risks are visible from recent news flow. With limited public information beyond the dividend announcement, the outlook appears stable but warrants monitoring for operational updates.
Quarterly Results
| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 210 | 225 | 222 | 172 | 160 | 171 | 173 | 221 | 234 | 251 | 229 | 236 |
| Expenses | 116 | 135 | 140 | 109 | 97 | 109 | 109 | 151 | 149 | 161 | 140 | 146 |
| Operating Profit | 95 | 90 | 82 | 64 | 63 | 62 | 64 | 70 | 85 | 90 | 89 | 89 |
| OPM % | 45% | 40% | 37% | 37% | 39% | 36% | 37% | 32% | 36% | 36% | 39% | 38% |
| Other Income | 1 | 1 | 3 | -24 | 3 | 2 | 5 | 12 | 3 | 5 | 6 | 6 |
| Interest | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 3 | 3 | 3 |
| PBT | 95 | 90 | 84 | 39 | 61 | 63 | 67 | 79 | 84 | 90 | 91 | 92 |
| Tax % | 25% | 24% | 25% | 25% | 26% | 29% | 25% | 23% | 25% | 27% | 25% | 25% |
| Net Profit | 71 | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 66 | 68 | 69 |
| EPS in Rs | — | — | — | 12.59 | 19.54 | 19.24 | 21.71 | 26.36 | 27.31 | 28.87 | 29.44 | 29.87 |
Profit & Loss
| Particulars | Dec 2023 8m | Dec 2024 | Mar 2025 | Dec 2025 | TTM |
|---|---|---|---|---|---|
| Sales | 555 | 724 | 878 | 878 | 950 |
| Expenses | 337 | 454 | 569 | 569 | 597 |
| Operating Profit | 219 | 271 | 309 | 309 | 353 |
| OPM % | 39% | 37% | 35% | 35% | 37% |
| Other Income | 2 | -15 | 25 | 25 | 20 |
| Interest | 0 | 4 | 2 | 2 | 2 |
| Depreciation | 2 | 4 | 12 | 12 | 13 |
| PBT | 219 | 247 | 320 | 320 | 357 |
| Tax % | 25% | 27% | 25% | 25% | — |
| Net Profit | 165 | 181 | 240 | 240 | 266 |
| EPS in Rs | — | 78.59 | 104 | 104 | 115 |
| Div. Payout % | 6% | 70% | 0% | 72% | — |
Balance Sheet
| Particulars | Dec 2023 | Dec 2024 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|
| Equity Capital | 2 | 23 | 23 | 23 |
| Reserves | 206 | 250 | 361 | 325 |
| Borrowings | 0 | 20 | 25 | 21 |
| Other Liabilities | 138 | 138 | 138 | 338 |
| Total Liabilities | 345 | 431 | 547 | 706 |
| Fixed Assets | 5 | 29 | 36 | 30 |
| CWIP | 3 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 338 | 402 | 511 | 677 |
| Total Assets | 345 | 431 | 547 | 706 |
Cash Flow
| Particulars | Dec 2023 | Dec 2024 | Mar 2025 | Dec 2025 |
|---|---|---|---|---|
| Operating | 0 | 439 | — | 175 |
| Investing | 0 | 2 | — | 8 |
| Financing | 2 | -116 | — | -134 |
| Net Cash Flow | 2 | 325 | — | 48 |
| Free Cash Flow | -4 | 429 | — | 167 |
| CFO/OP | 2 | 208 | — | 85 |
Ratios
| Particulars | Dec 2023 | Dec 2024 | Mar 2025 | Dec 2025 |
|---|---|---|---|---|
| Debtor Days | 21 | 7 | — | 12 |
| Inventory Days | 232 | 80 | — | 98 |
| Days Payable | 144 | 138 | — | 126 |
| Cash Conversion Cycle | 109 | -51 | — | -16 |
| Working Capital Days | 134 | -33 | — | -4 |
| ROCE % | — | 111% | — | 90% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sanofi Consumer Healthcare insights
57 extracted metrics + investor summaries across FY23–FY25.
Documents
Frequently Asked Questions about Sanofi Consumer Healthcare
What does Sanofi Consumer Healthcare India Ltd do?
Where is Sanofi Consumer Healthcare India Ltd (SANOFICONR) listed?
Which sector does Sanofi Consumer Healthcare India Ltd belong to?
What is the market capitalisation of Sanofi Consumer Healthcare India Ltd?
What is the PE ratio of Sanofi Consumer Healthcare India Ltd?
What is the 52-week high and low of Sanofi Consumer Healthcare India Ltd?
Does Sanofi Consumer Healthcare India Ltd pay dividends?
What is the Return on Equity (ROE) of Sanofi Consumer Healthcare India Ltd?
Company Information
Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products.[1]It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products. [2]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SANOFICONR.md for Sanofi Consumer Healthcare India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.